Investors Are Undervaluing Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) By 29.54%

Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Lee Kay

Fri, Jan 11, 2019, 6:54 PM

Today I will be providing a simple run through of a valuation method used to estimate the attractiveness of Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) as an investment opportunity by estimating the company’s future cash flows and discounting them to their present value. This is done using the Discounted Cash Flows (DCF) model. It may sound complicated, but actually it is quite simple! Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model. Please also note that this article was written in January 2019 so be sure check out the updated calculation by following the link below.

Check out our latest analysis for Advanced Enzyme Technologies

Want to help shape the future of investing tools and platforms? Take the survey and be part of one of the most advanced studies of stock market investors to date.

The method

I use what is known as a 2-stage model, which simply means we have two different periods of varying growth rates for the company’s cash flows. Generally the first stage is higher growth, and the second stage is a more stable growth phase. To start off with we need to estimate the next five years of cash flows. For this I used the consensus of the analysts covering the stock, as you can see below. The sum of these cash flows is then discounted to today’s value.

5-year cash flow forecast

	2019	2020	2021	2022	2023
Levered FCF (₹, Millions)	₹1.16k	₹1.51k	₹1.71k	₹1.93k	₹2.17k
Source	Analyst x1	Analyst x1	Est @ 12.88%	Est @ 12.88%	Est @ 12.88%
Present Value Discounted @ 13.55%	₹1.03k	₹1.17k	₹1.17k	₹1.16k	₹1.15k

Present Value of 5-year Cash Flow (PVCF)= ₹5.7b

After calculating the present value of future cash flows in the intial 5-year period we need to calculate the Terminal Value, which accounts for all the future cash flows beyond the first stage. For a number of reasons a very conservative growth rate is used that cannot exceed that of the GDP. In this case I have used the 10-year government bond rate (7.7%). In the same way as with the 5-year ‘growth’ period, we discount this to today’s value at a cost of equity of 13.5%.

Terminal Value (TV) = FCF₂₀₂₃ × (1 + g) ÷ (r – g) = ₹2.2b × (1 + 7.7%) ÷ (13.5% – 7.7%) = ₹40b

Present Value of Terminal Value (PVTV) = TV / (1 + r)⁵ = ₹40b ÷ ( 1 + 13.5%)⁵ = ₹21b

The total value, or equity value, is then the sum of the present value of the cash flows, which in this case is ₹27b. In the final step we divide the equity value by the number of shares outstanding. If the stock is an depositary receipt (represents a specified number of shares in a foreign corporation) or ADR then we use the equivalent number. This results in an intrinsic value of ₹244.47. Relative to the current share price of ₹172.25, the stock is about right, perhaps slightly undervalued at a 30% discount to what it is available for right now.

NSEI:ADVENZYMES Intrinsic Value Export January 12th 19

Important assumptions

I’d like to point out that the most important inputs to a discounted cash flow are the discount rate and of course the actual cash flows. If you don’t agree with my result, have a go at the calculation yourself and play with the assumptions. Because we are looking at Advanced Enzyme Technologies as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighed average cost of capital, WACC) which accounts for debt. In this calculation I’ve used 13.5%, which is based on a levered beta of 0.800. This is derived from the Bottom-Up Beta method based on comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

Next Steps:

Whilst important, DCF calculation shouldn’t be the only metric you look at when researching a company. What is the reason for the share price to differ from the intrinsic value? For ADVENZYMES, there are three fundamental aspects you should further examine:

Financial Health: Does ADVENZYMES have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.
Future Earnings: How does ADVENZYMES’s growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
Other High Quality Alternatives: Are there other high quality stocks you could be holding instead of ADVENZYMES? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!

PS. Simply Wall St does a DCF calculation for every IN stock every 6 hours, so if you want to find the intrinsic value of any other stock just search here.

To help readers see past the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price-sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned. For errors that warrant correction please contact the editor at editorial-team@simplywallst.com.

Terms and Privacy Policy

Your Privacy Choices

Utah Privacy Notice

More Info